Trial Profile
A open-label, two-period, fixed-sequence trial to study the effect of rifampin on the pharmacokinetics of ertugliflozin in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2018
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary) ; Rifampicin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 28 Aug 2018 Results published in the Clinical Therapeutics.
- 20 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics